How does CD20 Monoclonal Antibody PHE5 differ from other CD20 targeting therapies?

The CD20 Monoclonal Antibody PHE5 is carefully designed in the manner of ensuring that it is very specific in targeting any CD20-positive B-cells. Consistently such an antibody may pose a different avenue concerning immunogenicity, efficacy, and safety profile among the different CD20 therapeutics like rituximab, ocrelizumab, or ofatumumab. Evidently, PHE5 has certain unique attributes trodden in secrecy, the benefits of which would be reaped for focused research or therapeutic needs, and its attributes need to be weighed upon by researchers and clinical teams.

What are some potential applications or benefits that may ensue by applying NHP-derived CD20 MABs in research or therapy, such as PHE5?

NHP-derived antibodies, such as PHE5, offer a better approximation physiologically and immunologically toward humans, with the result that they tend to decrease immunogenicity and provide a better chance for success in applications to humans. They are, therefore, of pivotal significance for the study into a myriad of conditions of the immune system, B cell-mediated as they may be, from autoimmune diseases to unique forms of cancer, and as such provide by far new lead information significantly to therapeutic development and medical strategies relying on individualized approaches.

Category: Non-Human Primate (NHP) related Antibody Products

CD20 Monoclonal Antibody (PHE5) (NHP-AB225)

Product Overview Detailed Product Description Technical Specifications Product Property Target Information Downloadable Resources FAQs Customer Reviews

This product is an antibody that was generated by immunizing mouse against synthetic peptide. It is used only in in vitro assays.

Introduction: CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation. CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation. CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.

Conjugate: None

Antibody Isotype: IgG

Applications: ELISA; IF; IHC

Host Species: Mouse

Species Reactivity: Gibbon; Gorilla; Human; Monkey

Immunogen: Synthetic peptide

Purification: Ascites

Format: Liquid

Buffer: 0.03% sodium azide

Storage: Short term: 4˚C. Long term: Store at -20˚C. Avoid freeze-thaw cycles.

Clone: PHE5

Clonality: Monoclonal

Alternative Names: B-cell differentiation antigen Ly-44; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; B-lymphocyte surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; Leukocyte surface antigen Leu-16; Lymphocyte antigen 44; Membrane-spanning 4-domains subfamily A member 1; membrane-spanning 4-domains, subfamily A, member 1; membrane-spanning 4-domains, subfamily A, member 2; MGC3969

Entrez Gene ID: 931

CD20 Monoclonal Antibody (PHE5) (NHP-AB225) Data Sheet: Detailed information. datasheet

Q 1: How does CD20 Monoclonal Antibody PHE5 differ from other CD20 targeting therapies?
A: The CD20 Monoclonal Antibody PHE5 is carefully designed in the manner of ensuring that it is very specific in targeting any CD20-positive B-cells. Consistently such an antibody may pose a different avenue concerning immunogenicity, efficacy, and safety profile among the different CD20 therapeutics like rituximab, ocrelizumab, or ofatumumab. Evidently, PHE5 has certain unique attributes trodden in secrecy, the benefits of which would be reaped for focused research or therapeutic needs, and its attributes need to be weighed upon by researchers and clinical teams.
Q 2: What are some potential applications or benefits that may ensue by applying NHP-derived CD20 MABs in research or therapy, such as PHE5?
A: NHP-derived antibodies, such as PHE5, offer a better approximation physiologically and immunologically toward humans, with the result that they tend to decrease immunogenicity and provide a better chance for success in applications to humans. They are, therefore, of pivotal significance for the study into a myriad of conditions of the immune system, B cell-mediated as they may be, from autoimmune diseases to unique forms of cancer, and as such provide by far new lead information significantly to therapeutic development and medical strategies relying on individualized approaches.

Verifiable
By using CD20 Monoclonal Antibody (PHE5) from reactive biolabs, my experimental data are verifiable and the progress of my project is accelerated.

Click the button below to contact us or submit your feedback about this product.

Fig.1 Obesity can be counteracted by gene regulation.

Your research is unique, and we understand that standard products may not always fit. Our team of experts specializes in custom NHP sample collections. We can design a tailored protocol to meet your specific research requirements, including samples with unique anticoagulant types, customized volumes, or from specific disease models.